TOP1 Amplification

CI-VAR-00000212Explore in graph →CIViC 371

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm2
TOP1 Amplification	Cetuximab + FOLFIRI RegimenCombination	Predictive	B	Supports Sensitivity Response	4	accepted	EID12143 The OncoBird framework utilizes data from the open-label, randomized phase III FIRE-3 trial, which involved patients with metastatic colorectal carcinoma who received either cetuximab or bevacizumab i… (full text at CIViC) PMID 37666855 · Ohnmacht et al., 2023 · Open in CIViC	civic
TOP1 Amplification	Irinotecan	Predictive	B	Supports Sensitivity Response	1	accepted	EID888 FFPE tumor samples from 78 patients with colorectal cancer, who had received irinotecan monotherapy were analyzed with a FISH dual-probe. TOP1 gain was nonsignificantly associated with objective respo… (full text at CIViC) PMID 24256029 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.